Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh (RIGHT)

February 3, 2015 updated by: Mette Bredal Kristensen, University of Copenhagen
A dietary intervention study designed as a randomized, controlled, parallel intervention of 6-weeks duration. A total of 75 participants will be included in the study and randomly allocated to one of three interventions (refined wheat, whoelgrain wheat or wholegrain rye). Clinincal examinations including anthropometric assessment, fecal, urine and fastign blood sampling, dietary assessment and a meal challenge will be done before (week 0) and after (week 6) the intervention. At timepoints week 0, 2, 4 and 6 questionnaires will be filled in concerning satisfaction with diet and gastrointestinal symptoms.

Study Overview

Detailed Description

A dietary intervention study designed as a randomized, controlled, parallel intervention of 6-weeks duration. A total of 75 participants will be included in the study and randomly allocated to one of three interventions (refined wheat, whoelgrain wheat or wholegrain rye). The randomization will be stratified according to sex and sex-specific median habitual cereal dietary fibre intake (16g/d for men and 13g/d for women). The randomization will be done by means of a randomization generator of the webpage (http://www.randomization.com). Recruitment and randomization will take place continuously during the study period, and therefore randomization will be done as mixed block randomization.

During the intervention study, participants are instructed to substitute all cereal products (e.g. bread, breakfast cereals, pasta) of their diet with the provided study products. The amount of provided study products will match the average intake of carbohydrate-rich products of the Danish population, which corresponds to ~200g of bread and cereal products per day. The participants will eat the study products in an ad libitum manner and b instructed to avoid other cereals in their diet including cake, biscuits, ready made meals and fast foods with the exception of White rice whis is allowed 1-2 times per week.

Clinincal examinations including anthropometric assessment, fecal, urine and fastign blood sampling, dietary assessment and a meal challenge will be done before (week 0) and after (week 6) the intervention. At timepoints week 0, 2, 4 and 6 questionnaires will be filled in concerning satisfaction with diet and gastrointestinal symptoms.

Study Type

Interventional

Enrollment (Actual)

75

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • • Age: 30 - 65 years

    • Body mass index (BMI): 25 - 32 kg/m2
    • Weight stable (<3 kg weight change during the last 6 months)
    • Apparently healthy
    • Informed consent signed
    • Freezer capacity for 2 weeks bread provision
    • Can attend all visits required for the study

Exclusion Criteria:

  • • Smoking on a daily basis

    • Lactating (or lactating within 6 weeks prior to study start), pregnant (or pregnant within 3 months prior to study start) or wish to become pregnant during the study
    • Diagnosed with any form of diabetes or CVD
    • Reported chronic GI disorders
    • Antibiotic treatment 3 month before study start and during the study
    • Use of pre- or probiotic 1 month before study start and during the study
    • Lack of cooperation and adherence to the protocol
    • Use of prescription medication will be evaluated on an individual basis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Refined wheat
Refined wheat grain, a variety of cereal foods providing no wholegrain
A variety of cereal foods providing 0g/day wholegrain
Experimental: Wholegrain wheat
Wholegrain wheat grain, a variety of cereal foods providing >100g wheat wholegrain/day
A variety of cereal foods providing >100g/day wholegrain from wheat
Experimental: Wholegrain rye
Wholegrain rye grain, a variety of cereal foods providing >100g rye wholegrain/day
A variety of cereal foods providing >100g/day wholegrain from rye

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gastrointestinal symptoms evaluated by questionnaires (100mm visual analogue scales)
Time Frame: Change from 0 to 6 weeks
Subjective sensations of gastrointestinal symptoms evaluated by questionnaires (100mm visual analogue scales)
Change from 0 to 6 weeks
Gut microbiota composition assessed using 16S in a single fecal sample
Time Frame: Change from 0 to 6 weeks
Gut microbiota compostion assessed using 16S in a single fecal sample
Change from 0 to 6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anthropometric masures
Time Frame: Change from 0 to 6 weeks
Body weight and waist circumference, saggital abdominal diameter and body composition (fat mass and fat free mass assessed using DEXA)
Change from 0 to 6 weeks
Blood pressure
Time Frame: Change from 0 to 6 weeks
Diastolic and systolic blood pressure and heart rate assessed twice using an automated apparatus
Change from 0 to 6 weeks
Blood lipids, fasting concentrations of total, LDL and HDL cholesterol and triglyerides
Time Frame: Change from 0 to 6 weeks
Fasting concentrations of total, LDL and HDL cholesterol and triglyerides
Change from 0 to 6 weeks
Glucose metabolism, fasting concentrations of glucose, insulin and HbA1C as calculation of HOMA-IR
Time Frame: Change from 0 to 6 weeks
Fasting concentrations of glucose, insulin and HbA1C as calculation of HOMA-IR
Change from 0 to 6 weeks
Low-grade inflammation, fasting concentrations of hsCRP, IL-6, IL-10, and TNF-a
Time Frame: Change from 0 to 6 weeks
Fasting concentrations of hsCRP, IL-6, IL-10, and TNF-a
Change from 0 to 6 weeks
Appetite sensation
Time Frame: Change from 0 to 6 weeks
Fasting and postprandial (every 30 minutes for 240 minutes) sensation of hunger, satiety, fullness, prospective food intake, thirst and well being
Change from 0 to 6 weeks
Breath hydrogen assessed using a Hydrolyzer
Time Frame: Change from 0 to 6 weeks
Fasting and postprandial (every 30 minutes for 240 minutes) concentrations of H2 in exhaled breath assessed using a Hydrolyzer
Change from 0 to 6 weeks
Short chain fatty acids, fecal concentrations of short chain fatty acids
Time Frame: Change from 0 to 6 weeks
Fecal concentrations of short chain fatty acids
Change from 0 to 6 weeks
Fecal pH
Time Frame: Change from 0 to 6 weeks
Fecal pH assessed in homogenized fecal sample
Change from 0 to 6 weeks
Intestinal permeability, assessed by urinary excretion of lactulose and mannitol
Time Frame: Change from 0 to 6 weeks
Intestinal permeability is assessed by urinary excretion of lactulose and mannitol for 4 hours and 24 hours following an oral load of 10g lactulose and 2 g mannitol
Change from 0 to 6 weeks
Zonulin, fasting concentrations in plasma
Time Frame: Change from 0 to 6 weeks
Fasting concentrations of zonulin in plasma
Change from 0 to 6 weeks
Dietary intake, a weighted 4-day food record
Time Frame: Change from 0 to 6 weeks
a weighted 4-day food record will be used to assess energy intake and macronutrient (protein, fat, carbohydrates and dietaru fiber) composition
Change from 0 to 6 weeks
Compliance, measured by fasting plasma alkylresorcinol concentrations will be used as a biomarker of wholegrain wheat and rye intake
Time Frame: Change from 0 to 6 weeks
Fasting plasma alkylresorcinol concentrations will be used as a biomarker of wholegrain wheat and rye intake
Change from 0 to 6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2014

Primary Completion (Actual)

December 1, 2014

Study Completion (Anticipated)

December 1, 2015

Study Registration Dates

First Submitted

January 21, 2015

First Submitted That Met QC Criteria

February 3, 2015

First Posted (Estimate)

February 6, 2015

Study Record Updates

Last Update Posted (Estimate)

February 6, 2015

Last Update Submitted That Met QC Criteria

February 3, 2015

Last Verified

February 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • H-1-2014-062

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastrointestinal Diseases

Clinical Trials on Refined wheat

3
Subscribe